We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ETNB market cap is 929.67M. The company's latest EPS is USD -1.3398 and P/E is -6.54.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -42.13M | -39.35M | -41.21M | -57.28M | -53.44M |
| Net Income | -38.39M | -34.73M | -40.24M | -51.68M | -47.97M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -26.64M | -49.36M | -89.74M | -102.25M | -151.2M |
| Net Income | -57.42M | -49.5M | -90.12M | -102.03M | -142.19M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 492.51M | 460.11M | 596.27M | 577.32M | 582.14M |
| Total Liabilities | 50.53M | 49.9M | 59.96M | 66.78M | 67.22M |
| Total Equity | 441.99M | 410.21M | 536.31M | 510.54M | 514.92M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 95.55M | 211.07M | 162.42M | 196.82M | 596.27M |
| Total Liabilities | 5.61M | 8.11M | 36.47M | 44.99M | 59.96M |
| Total Equity | 89.94M | 202.96M | 125.96M | 151.83M | 536.31M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -64.53M | -94.89M | -129.19M | -39.72M | -100.88M |
| Investing | -97.7M | -59.38M | -123.02M | -79.9M | -52.05M |
| Financing | 352.42M | 350.94M | 513.11M | 21.03M | 48.99M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -25.46M | -46.24M | -76.78M | -81.09M | -129.19M |
| Investing | -139k | -106.83M | 7.16M | -33.94M | -123.02M |
| Financing | 107.7M | 157.92M | 23.87M | 117.83M | 513.11M |
| Market Cap | 929.67M |
| Price to Earnings Ratio | -6.54 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 2.94 |
| Price to Book Ratio | 1.73 |
| Dividend Yield | - |
| Shares Outstanding | 106.13M |
| Average Volume (1 week) | 977.6k |
| Average Volume (1 Month) | 987.68k |
| 52 Week Change | 12.60% |
| 52 Week High | 16.63 |
| 52 Week Low | 7.00 |
| Spread (Intraday) | 1.05 (11.05%) |
| Company Name | 89bio Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.89bio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
